IGF1 and acromegaly: On the other hand, pegvisomant has been demonstrated to effectively control IGF-I levels while improving glucose metabolism (39, 40), obstructive sleep apnea (41), and arrhythmiasin acromegaly patients (42), with neutral or potentially beneficial effects on cardiovascular outcomes (43).